血必净对脓毒症患者去甲肾上腺素用量的影响

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (484 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective To investigate the effect of Xuebijing Injection(XBJ)on Norepinephrine(NE)in early stage of sepsis.Methods A total of 108 patients with sepsis requiring NE from March 2020 to March 2023 in Guangzhou Hospital of Integrated Traditional Chinese and Western Medicine were selected as research objects.On the basis of the same fluid resuscitation,they were divided into observation group(n=54)and control group(n=54)according to random number table method.Observation group was treated with XBJ 50 ml+0.9% Sodium Chloride Solution 100 ml,once every 12 hours.The control group was infused with 150 ml 0.9% Sodium Chloride Solution every 12 hours under the condition of basic treatment.NE dosage,procalcitonin(PCT),interleukin-6(IL-6),C-reactive protein(CRP),white blood cell count(WBC),neutrophil/lymphocyte ratio(NLR),platelet(PLT),lactate(Lac),sequential organ failure assessment(SOFA),acute physiology and chronic health assessment Ⅱ (APACHEⅡ),and length of ICU stay of the two groups were observed.Results There was no significant difference in NE dosage between two groups when MAP≥65 mmHg level was maintained(P＞0.05).However,the total NE consumption in the observation group was lower than that in the control group,and the difference was statistically significant (P＜0.05).The total NE use time of observation group was shorter than that of control group,and the difference was statistically significant (P＜0.05).The scores of PCT,IL-6,CRP,NLR,Lac,SOFA and APACHEⅡin observation group were lower than those in control group,with statistical significances (P＜0.05).There were no significant differences in WBC,PLT and length of ICU stay between the two groups(P＞0.05).Conclusion XBJ in early stage of sepsis can effectively reduce NE dosage,reduce inflammation and improve circulation.

Key words： Xuebijing Injection Norepinephrine Sepsis Inflammation Microcirculation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIANG Zhifeng WANG Zhenkui HUANG Wendong FU Zhenghui

Cite this article:

LIANG Zhifeng WANG Zhenkui HUANG Wendong FU Zhenghui. Effect of Xuebijing Injection on the dosage of Norepinephrine in patients with sepsis[J]. 中国当代医药, 2024, 31(12): 27-31.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2024/V31/I12/27

[1]	Evans L，Rhodes A，Alhazzani W，et al.Surviving sepsis campaign：international guidelines for management of sepsis and septic shock 2021[J].Intensive Care Med，2021，47（11）：1181-1247.
[2]	Auchet T，Rengier MA，Girerd N，et al.Outcome of patients with septic shock and high-dose vasopressor therapy[J].Ann Intensive Care，2017，7（1）：43.
[3]	Zhou W，Lai X，Wang X，et al.Network pharmacology to explore the anti-inflammatory mechanism of Xuebijing in the treatment of sepsis[J].Phytomedicine，2021，85：153543.
[4]	Wang L，Liu Z，Dong Z，et al.Effects of Xuebijing injection on microcirculation in septic shock[J].J Surg Res，2016，202（1）：147-154.
[5]	Li C，Wang P，Li M，et al.The current evidence for the treatment of sepsis with Xuebijing injection：Bioactive constituents，findings of clinical studies and potential mechanisms[J].J Ethnopharmacol，2021，265：113301.
[6]	曹钰，柴艳芬，邓颖，等.中国脓毒症/脓毒性休克急诊治疗指南（2018）[J].临床急诊杂志，2018，19（9）：567-588.
[7]	郜亚，许铁，燕宪亮，等.早期液体复苏剂量对脓毒性休克患者预后的影响[J].中国急救复苏与灾害医学杂志，2023，18（9）：1180-1184.
[8]	Matsuda J，Kato S，Yano H，et al.The Sequential Organ Failure Assessment（SOFA）score predicts mortality and neurological outcome in patients with post-cardiac arrest syndrome[J].J Cardiol，2020，76（3）：295-302.
[9]	姚乐，赵浩，张洁，等.急性生理和慢性健康状况评分Ⅱ和序贯器官衰竭评估评分对急诊重症监护病房脓毒症患者的预后评估价值[J].中国临床医生杂志，2018，46（3）：276-278.
[10]	Yajnik V，Maarouf R.Sepsis and the microcirculation：the impact on outcomes[J].Curr Opin Anaesthesiol，2022，35（2）：230-235.
[11]	曹书华，王今达，李银平.从“菌毒并治”到“四证四法”——关于中西医结合治疗多器官功能障碍综合征辨证思路的深入与完善[J].中国危重病急救医学，2005（11）：7-9.
[12]	周慧，沈利.血液净化联合血必净治疗重症烧伤的临床研究[J].中国医药科学，2023，13（5）：193-196.
[13]	张文媛.血必净和乌司他丁单独用药及联合用药对多发伤患者的有效性分析[J].中国医药科学，2023，13（18）：73-76，93.
[14]	刘欣，陈辉，林洁，等.血必净注射液对重症急性胰腺炎的临床效果及对炎症因子水平的调节作用[J].中国当代医药，2022，29（5）：43-45.
[15]	李陆军，马蓉，曹越.血必净注射液治疗脓毒症的药理作用机制研究进展[J].药物评价研究，2018，41（8）：1548-1553.
[16]	Liu S，Yao C，Xie J，et al.Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis：The EXIT-SEP Randomized Clinical Trial[J].JAMA Intern Med，2023，183（7）：647-655.
[17]	Song Y，Yao C，Yao Y，et al.XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia：A Randomized Controlled Trial[J].Crit Care Med，2019，47（9）：e735-e743.
[18]	Guo J，Zhu J，Wang Q，et al.Comparative Efficacy of Seven Kinds of Chinese Medicine Injections in Acute Lung Injury and Acute Respiratory Distress Syndrome：A Network Metaanalysis of Randomized Controlled Trials[J].Front Pharmacol，2021，12：627751.
[19]	Chen H，Bai Z，Li H，et al.Efficacy of Xuebijing Injection for Acute Pancreatitis：A Systematic Review and Meta-Analysis of Randomized Controlled Trials[J].Evid Based Complement Alternat Med，2021，2021：6621368.
[20]	Gotts JE，Matthay MA.Sepsis：pathophysiology and clinical management[J].BMJ，2016，353：i1585.
[21]	Tian S，Qin D，Ye Y，et al.Scientific Evidence of Xuebijing Injection in the Treatment of Sepsis[J].Evid Based Complement Alternat Med，2021，2021：6879278.
[22]	Li C，Wang P，Zhang L，et al.Efficacy and safety of Xuebijing injection（a Chinese patent）for sepsis：A meta-analysis of randomized controlled trials[J].J Ethnopharmacol，2018，224：512-521.
[23]	Cao L，Li Z，Ren Y，et al.Xuebijing Protects Against Septic Acute Liver Injury Based on Regulation of GSK-3beta Pathway[J].Front Pharmacol，2021，12：627716.
[24]	Jin ZH，Zhao XQ，Sun HB，et al.Effect of Xuebijing injection on myocardium during cardiopulmonary bypass：A prospective，randomized，double blind trial[J].World J Clin Cases，2022，10（13）：4110-4118.
[25]	Hu HX，Zhu MQ，Sun YC，et al.Xuebijing enhances neuroprotective effects of ulinastatin on transient cerebral ischemia via Nrf2-are signal pathways in the hippocampus[J].J Biol Regul Homeost Agents，2018，32（5）：1143-1149.